| Active substance | talazoparib |
| Holder | Pfizer NV/SA |
| Status | Running |
| Indication | in combination with Xtandi (enzalutamide) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 27/11/2023 |